Adaptive Biotechnologies (NASDAQ:ADPT) Stock: Insider Julie Rubinstein Sells 11,881 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $28.45, for a total transaction of $338,014.45. Following the transaction, the chief operating officer directly owned 377,802 shares in the company, valued at $10,748,466.90. This trade represents a 3.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Monday, October 26th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $26.04, for a total transaction of $309,381.24.
• On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.98, for a total transaction of $296,787.38.
• On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.05, for a total transaction of $285,738.05.
• On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.41, for a total transaction of $301,896.21.
• On Thursday, October 15th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.61, for a total transaction of $304,272.41.
• On Tuesday, October 13th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.50, for a total transaction of $302,965.50.
• On Thursday, October 8th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.66, for a total transaction of $304,866.46.
• On Monday, October 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $29.19, for a total value of $346,806.39.
• On Friday, October 2nd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $28.13, for a total value of $334,212.53.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock opened at $26.64 on Friday. The stock has a 50 day moving average of $26.38 and a 200 day moving average of $19.64. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. Adaptive Biotechnologies Corporation has a fifty-two week low of $12.00 and a fifty-two week high of $30.74.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The business had revenue of $71.55 million during the quarter, compared to analysts’ expectations of $65.44 million. During the same quarter in the prior year, the firm earned ($0.17) EPS. Adaptive Biotechnologies’s revenue for the quarter was up 21.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.40 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Adaptive Biotechnologies

Several hedge funds have recently bought and sold shares of the company. Arizona State Retirement System boosted its stake in Adaptive Biotechnologies by 1.3% in the 2nd quarter. Arizona State Retirement System now owns 31,866 shares of the company’s stock worth $684,000 after buying an additional 416 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in Adaptive Biotechnologies by 6.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock valued at $205,000 after buying an additional 941 shares during the period. Gibbs Wealth Management increased its stake in shares of Adaptive Biotechnologies by 4.6% during the 3rd quarter. Gibbs Wealth Management now owns 26,900 shares of the company’s stock valued at $777,000 after acquiring an additional 1,191 shares during the last quarter. Assetmark Inc. increased its stake in shares of Adaptive Biotechnologies by 46.4% during the 1st quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock valued at $61,000 after acquiring an additional 1,401 shares during the last quarter. Finally, Nykredit A S acquired a new stake in shares of Adaptive Biotechnologies in the second quarter worth approximately $31,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

Analyst Ratings Changes

ADPT has been the subject of a number of recent analyst reports. The Goldman Sachs Group started coverage on Adaptive Biotechnologies in a research report on Tuesday, September 29th. They set a “buy” rating and a $35.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Thursday, October 15th. TD Cowen upped their target price on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. National Bank Financial set a $34.00 target price on shares of Adaptive Biotechnologies in a research note on Tuesday, September 22nd. Finally, BTIG Research lifted their price target on shares of Adaptive Biotechnologies from $25.00 to $34.00 and gave the company a “buy” rating in a research report on Tuesday, September 22nd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus price target of $30.06.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.